Lttl

Getting started with Lttl begins with a free online health assessment described as taking about two minutes. A licensed U.S. clinician reviews the responses and determines whether treatment is medically appropriate before building a personalized plan — the company is explicit that a prescription isn’t guaranteed and clinicians can decline to prescribe. Approved orders ship, according to Lttl, within 48 hours of prescribing, with orders generally taking 2–5 business days to ship after the prescription is issued and 3–7 business days to arrive after that.

Lttl publishes its own outcome figures for its GLP-1 plans: it states that average members lose 32 lbs in the first 6 months on both the semaglutide and tirzepatide plans, with “top responders” losing 44+ lbs (semaglutide) or 55+ lbs (tirzepatide) over 12 months. These are Lttl’s own reported figures rather than independently verified clinical data.

Beyond weight-loss GLP-1 plans, Lttl offers a microdose track described as “gentle, steady metabolic support,” plus a separate longevity-peptide lineup: Sermorelin, NAD+, glutathione, MIC B12, and L-carnitine, alongside methylene blue. Each vertical is offered as its own subscription rather than an add-on to the weight-loss plan, based on the site’s plan structure.

On the NAD+ injections specifically, Lttl markets benefits including increased energy, sharper memory and focus, reduced inflammation, cellular DNA support, and faster athletic recovery, with NAD+ pricing starting at $99 a month on Lttl’s dedicated NAD+ offer page.

The intake process is designed to be quick — a free assessment the company describes as taking about two minutes, followed by clinician review and, per Lttl, prescribing and shipping within 48 hours when approved. Members manage their plan and reach support through a 24/7 patient portal at portal.lttl.com.

Lttl advertises “unlimited 24/7 support” alongside phone, email, and patient-portal access, and states members can cancel their subscription at any time from their account or by emailing the support team, with no long-term contract.

Lttl states its compounded medications are made by FDA-registered pharmacy partners under board-certified clinicians, and describes itself as LegitScript verified. The company is direct about the regulatory status of its products: compounded medications “are produced in FDA-registered facilities but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.” Lttl’s FAQ also discloses common GLP-1 side effects — nausea, vomiting, diarrhea, constipation, and fatigue — and notes that clinicians discuss risks before prescribing and can decline to prescribe if treatment isn’t medically appropriate. The company states that its service is not a substitute for a patient’s regular primary care physician or in-person evaluation.